Resveratrol Targets CAF-Driven Breast Cancer Growth via VCAN Suppression

Study Background and Research Question

Breast cancer (BC) remains the most prevalent malignancy among women and a leading cause of cancer-related mortality worldwide. Despite advancements in surgery and targeted therapies, relapse and drug resistance persist, especially in advanced disease stages. A critical contributor to this therapeutic challenge is the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), which promote tumor growth and impede treatment efficacy. Conventional two-dimensional (2D) cell culture models fail to recapitulate the complex interactions between tumor cells and CAFs, often leading to misleading efficacy profiles for anti-cancer agents. The present study by Shi et al. (DOI:10.1016/j.intimp.2025.114451) aims to address this gap by employing a patient-derived organoid model to elucidate the impact of resveratrol—a polyphenolic compound with reported anti-tumor properties—on breast cancer cells protected by CAFs, with a particular focus on the mechanistic role of versican (VCAN) expression.

Key Innovation from the Reference Study

The central innovation of this research lies in the establishment and utilization of a hybrid co-culture system comprising patient-derived breast cancer organoids (BCOs) and matched CAFs. This three-dimensional, organoid-based model more faithfully mimics the in vivo tumor architecture and stromal interactions than traditional 2D cultures. The study uniquely investigates the protective role of CAFs in promoting organoid growth and drug resistance, while simultaneously evaluating the ability of resveratrol to overcome this protection by modulating VCAN expression. This approach provides a more clinically relevant platform for preclinical drug assessment and mechanistic investigation.

Methods and Experimental Design Insights

The research team collected surgical breast cancer specimens from patients to generate BCOs, which were validated through pathological examination. CAFs were isolated from the same samples and characterized using immunofluorescence markers. The BCO-CAF co-culture model was established to assess the influence of CAFs on tumor organoid proliferation, survival, and drug resistance.

To evaluate the anti-proliferative effects of resveratrol, the study implemented EdU-based proliferation assays—where 5-ethynyl-2'-deoxyuridine is incorporated into newly synthesized DNA during the cell cycle S-phase—alongside calcein-AM/propidium iodide (PI) viability staining. VCAN expression in CAFs, both at the mRNA and protein levels, was quantified using qRT-PCR, immunohistochemistry, and Western blotting following resveratrol treatment.

Protocol Parameters

• Organoid culture: Patient-derived breast cancer tissue processed and embedded in 3D matrix; organoids confirmed by pathological examination.
• CAFs isolation and characterization: Isolated via enzymatic digestion, confirmed by immunofluorescence for CAF markers.
• Co-culture setup: BCOs and CAFs co-cultured to simulate tumor-stroma interaction.
• Drug treatment: Resveratrol administered at experimentally defined concentrations; duration based on proliferation/viability endpoints.
• EdU proliferation assay: EdU incorporated into DNA during S-phase, detected through click chemistry and fluorescence microscopy.
• VCAN/TGF-β analysis: Quantified via immunohistochemistry, qRT-PCR, and Western blotting in CAFs post-treatment.

Core Findings and Why They Matter

Out of 19 patient-derived BCO cases, 15 (78.95%) demonstrated significant growth inhibition in response to resveratrol, as shown in the reference study. CAFs were found to markedly promote organoid growth by approximately 70%, underscoring their role in conferring tumor resilience. Importantly, resveratrol treatment not only neutralized this CAF-mediated protective effect but also induced extensive cell death in the co-culture system, with cell death rates approaching 85% in CAF-coated BCOs. Mechanistically, this anti-tumor effect was associated with significant downregulation of VCAN and TGF-β expression in CAFs, supporting the hypothesis that resveratrol disrupts CAF-driven signaling pathways essential for tumor proliferation and survival.

These results emphasize the importance of targeting stromal components—particularly CAFs and their secreted factors such as VCAN—as part of an integrated therapeutic strategy for breast cancer. The organoid co-culture platform demonstrated in this study provides a robust preclinical tool for dissecting tumor-stroma-drug interactions and identifying new intervention points that may translate into improved clinical outcomes.

Comparison with Existing Internal Articles

The workflow for assessing cell proliferation in this study relied on EdU incorporation, a method increasingly adopted for its sensitivity and compatibility with advanced imaging modalities. Multiple internal resources elaborate on the technical merits and applications of EdU-based assays:

• The article "EdU Imaging Kits (Cy3): Unraveling Cell Proliferation and..." details how click chemistry-based EdU assays enable high-resolution DNA synthesis detection, supporting studies that require precise S-phase quantification in cancer and drug resistance research—directly relevant to the experimental setup of the present study.
• For laboratories seeking replicable workflow guidance, "Scenario-Driven Solutions with EdU Imaging Kits (Cy3): Pr..." discusses protocol optimization and troubleshooting for EdU imaging, as well as comparisons with traditional BrdU-based approaches in genotoxicity testing and proliferation profiling.
• The internal review "EdU Imaging Kits (Cy3): Advanced Cell Proliferation and D..." offers further mechanistic insight into how click chemistry DNA synthesis detection advances studies on cell cycle dynamics and drug response, reinforcing the methodological rigor seen in the referenced organoid model research.

Together, these articles contextualize the choice of EdU-based imaging within a broader landscape of cell proliferation and S-phase measurement technologies, highlighting the importance of protocol specificity and workflow integration for translational oncology research.

Limitations and Transferability

While the hybrid organoid-CAF co-culture system offers superior physiological relevance compared to 2D models, certain limitations must be acknowledged. The model, though patient-derived, cannot fully recapitulate the complexity of immune and vascular interactions present in vivo. The focus on VCAN and TGF-β signaling, while mechanistically justified, does not encompass all potential pathways through which CAFs may mediate drug resistance. Additionally, the sample size—though substantial for organoid research—may not fully capture inter-patient heterogeneity. Prospective studies incorporating a wider array of patient-derived samples and integrating additional microenvironmental components could further validate and expand these findings.

Research Support Resources

For researchers interested in applying similar workflows, validated reagents such as the EdU Imaging Kits (Cy3) (SKU K1075) from APExBIO offer a sensitive and reliable method for quantifying cell cycle S-phase DNA synthesis using copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. These kits streamline fluorescence microscopy cell proliferation assays and are well-suited for advanced applications in organoid and co-culture models. By leveraging such tools, laboratories can enhance the precision and reproducibility of cell proliferation and genotoxicity testing in complex experimental systems.